About David Fallace
David Fallace is managing partner and co-founder of Cure Ventures. He is a director at Crosslink, which develops cancer drugs designed to assemble inside solid tumors. He also serves on the boards of Cenos Therapeutics, Kenai Therapeutics and Kobuk Therapeutics. He is a Tasca Therapeutics board director and a board observer at Recuro Health. He has also served as president and CEO of some new Cure biotechnology companies.
Fallace has invested in venture capital and alternative asset funds for more than 20 years. He served on investment committees overseeing alternative portfolios at several multibillion-dollar firms. His work included limited-partner stakes and founding investments in startups. He previously advised Polaris Partners on biotechnology and health care technology investments. He joined an expert-in-residence program at Harvard University's Office of Technology Development. Earlier, he was a managing director at TIFF Investment Management, where he headed $2.5 billion in diversifying strategies. He holds J.D. and M.B.A. degrees.
Experience
This experience comes from official bios, from David Fallace's profile and from SEC filings. For roles taken from filings, the years are when the filings name David Fallace in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people David Fallace works with at each company, as listed on that company's latest Form D.
